Hudson Bay Capital Management
IMVT icon

Hudson Bay Capital Management’s Immunovant IMVT Stock Holding History

Hudson Bay Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-184,600
Closed -$3.5M – 861
2023
Q2 		$3.5M Buy
+184,600
New +$3.44M 0.03% 393

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Hudson Bay Capital Management's IMVT Position: Q1 2026 in Review

Hudson Bay Capital Management opened a new position in Immunovant (IMVT) in Q1 2026: 19,230 shares worth $478K. The stake represents ﹤0.01% of the portfolio and ranks #984 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in IMVT as recently as Q3 2025.

Hudson Bay Capital Management first reported a position in IMVT in Q3 2024 and has held it in 6 quarters since. The position peaked at $2.76M in Q1 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Hudson Bay Capital Management held 19,230 shares of Immunovant worth $478K as of Q1 2026.
  • Immunovant was a new Hudson Bay Capital Management position in Q1 2026.
  • Immunovant made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #984 holding.
  • Hudson Bay Capital Management first reported a position in Immunovant in Q3 2024 and has held it in 6 quarters since.
  • Hudson Bay Capital Management's Immunovant position peaked at $2.76M in Q1 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.